Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4534972

C[C@]1(Cc2ccccc2)CN(c2ncc(C(=O)Nc3ccccc3N)cn2)CCN1C(=O)O.O=C(O)C(F)(F)F

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 20/20 0.53
HDAC3 O15379 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
CYP2C9 P11712 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
MAPKAPK3 Q16644 1/20 0.44
HDAC4 P56524 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
KCNH2 Q12809 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4532581 0.95 HDAC1 (0.57) HDAC1HDAC3HDAC2HDAC8CYP2C9
SCHEMBL4535217 0.85 HDAC1 (0.72) HDAC1HDAC3HDAC2HDAC8CYP2C9
SCHEMBL4539216 0.85 HDAC1 (0.72) HDAC1HDAC3HDAC2HDAC8CYP2C9
SCHEMBL4538583 0.77 HDAC1 (0.49) HDAC1HDAC3HDAC2HDAC8CYP2C9
SCHEMBL4534468 0.76 HDAC2 (0.67) HDAC1HDAC3HDAC2KCNH2
Trifluoroacetic Acid SCHEMBL4533810 0.75 HDAC1 (0.75) HDAC1HDAC3HDAC2HDAC8CYP2C9
SCHEMBL4541775 0.75 HDAC1 (0.68) HDAC1HDAC3HDAC2HDAC8CYP2C9
SCHEMBL4536266 0.73 HDAC1 (0.65) HDAC1HDAC3HDAC2HDAC8CYP2C9
SCHEMBL4538647 0.71 HDAC1 (0.48) HDAC1HDAC3HDAC2HDAC8CYP2C9
SCHEMBL4539704 0.71 HDAC1 (0.48) HDAC1HDAC3HDAC2HDAC8CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105264-A1 Substituted Nicotinamide Compounds MERCK SHARP & DOHME CORP. 2009-04-23 US claimed
US-20090105264-A1 Substituted Nicotinamide Compounds MERCK SHARP & DOHME CORP. 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105264-A1 Substituted Nicotinamide Compounds SIRT1, NQO1, TXNRD2 HDAC1 15/4885HDAC3 16/4885HDAC2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.